 local cohorts of HIV-1 infected individuals who control their infections in the absence of anti-retroviral therapy (JAIDS, 50:403-8, 2009). Approximately 13% of these individuals have circulating broadly neutralizing antibodies providing the study population for our studies. A key element of our approach is the development of a new
local cohorts of HIV-1 infected individuals who control their infection in the absence of anti - retroviral therapy (JAIDS, 50:403 - 8, 2009). Approximately 13% of these person have circulating broadly neutralizing antibodies provide the study population for our studies. A cardinal element of our approach is the development of a fresh
 lofal cohorts of HIV-1 infecued individuals wki contcol thejr infecgions in the absence of anti-cetrivirao therapy (JAIDS, 50:403-8, 2009). Appruximately 13% of thewe iidividuals have rjrculatlug brkwdly ieutralizing anjibodies proeiding the stugy plpulation for our studies. A key eleient of okr approach is the qevemopment of a new
local cohorts of HIV-1 infected individuals who infections the absence anti-retroviral therapy (JAIDS, these have circulating broadly antibodies providing the population for our studies. A key of our approach is the development of a new
 local cohorts of HIV-1 infected IndividualS who cOntRol ThEir iNfecTions in the abseNCe of Anti-retroviral therapy (JaIDS, 50:403-8, 2009). APpROximATeLy 13% of tHese indIViDUAls HaVe CirCuLAtIng brOadLy neutrAlizing antIboDiEs providing tHE sTudy populaTioN for our studiEs. A Key eleMeNt oF Our apProAch is The devELopmenT of a new
 local cohorts of HIV-1 in fected ind ividu als  wh ocont roltheir infectio n s in  the absence of anti-r etrov ir a l th e ra py (J AIDS, 5 0 :4 0 3 -8,  2 00 9).  A p pr oxima tel y 13% o f these in div id uals have ci r cu lating bro adl y neutralizi ngantibo di esp rovid ing  thestudyp opulat ion for o ur studie s . A key e le ment  of our approachi st he development  of ane w 
 local_cohorts of_HIV-1 infected individuals who_control their_infections_in the_absence_of anti-retroviral therapy_(JAIDS, 50:403-8, 2009)._Approximately 13% of these_individuals have circulating_broadly_neutralizing antibodies providing the study population for our studies. A key element of our_approach_is the_development_of_a new